Loading...
Docoh

Aptinyx (APTX)

Participants
Nick Smith Senior Director, Corporate Development and Investor Relations
Norbert Riedel President and Chief Executive Officer
Ashish Khanna Chief Financial Officer and Chief Business Officer
Andy Kidd Chief Operating Officer
Catherine King Senior Vice President, Clinical Development
Marc Goodman SVB Leerink
Charles Duncan Cantor Fitzgerald
Laura Chico Wedbush Securities
Gary Nachman BMO Capital Markets
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.
Operator

Good afternoon and welcome to the Aptinyx Fourth Quarter and Year End 2019 Financial Results Conference Call. At this time, all participants are on a listen-only mode.

Following the formal remarks, we will open up the call for questions. Please be advised today’s is recorded at the company’s request.

At this time, I’d like to turn the call over to Nick Smith, Senior Director of Corporate Development and Investor Relations at Aptinyx. proceed. please Nick,

Nick Smith

Good us Valerie. fourth and you operating thank and Thank today’s morning, conference joining results. and financial on end Aptinyx’s call for year you, XXXX everyone to quarter discuss

updates company website. and results financial press is on now release our available Our

Officer our results. Riedel, Financial our Officer business will our Chief Officer President Chief call, Norbert on Khanna, clinical our progress, and will and and review financial and Today review Business the Executive Chief then Ashish

Officer Operating us and King, addition, portion Andy Chief In Clinical with our Vice Senior are of of for Catherine President Kidd, our Q&A the Development call. the

statements Act Before these this subsequent results XXXX, the to in and risks made the Please that to conference like within which see are any remind disclaim can company’s during risk statements include obligation uncertainties results to forward-looking in as SEC. cause will forward-looking statements Reform we with forward-looking Any only statements made forward-looking and Private we afternoon differ of current and statements. begin, call and the materially. meaning the issued involve this everyone I’d of today actual disclaimer our update filings that factors of Litigation Securities the release financial

pleasure It’s over turn to now to my call the Norbert.

Norbert Riedel

have industry. afternoon Thank events significant Recent a times. and joining us ongoing you, related especially our world around appreciate created We extraordinary uncertainty to good Nick challenging pandemic and on COVID-XX during and within you everyone. degree our these the call the of today,

also having our the is COVID-XX our made progress on with communicate we us our backdrop, pipeline to shareholders on to is an you across it impact think update for have specifically. important provide the that business Against programs and very we to

relentless in for novel impacts, those the from was The patients year milestones by challenging made CNS support of of by XXXX. I'd with developing our therapies disorders. into mission we our and in getting numerous like to clinical execution team significant marked review progress the to Before suffering

centered to At all into of the set of for of Thanks goals clinical those initiated we X our that advancing around accomplished last goals candidates development studies Phase the three we outset last product X and year, terrific efforts four new Phase team, our study. ambitious year. clinical stage

studies throughout ability compound These development I characterize evaluate address and of pain, progress. in everything our PTSD unmet the the and novel the achieve to will needs am to of year that of teams very chronic accomplished impairment. the cognitive proud significant areas

been our momentum across important It and is have our good we XXXX continued also making each progress to have into note of that studies.

Of course, in the decisions regarding we of pandemic, throughout like and by our industry activities. light some our experiencing we have COVID-XX made introduced challenges development many these certain are clinical challenges

people compound XXXX NYX-XXX, Let’s X in is In in along. began that study and with an an on furthest patients by in The first NYX-XXX array with patients evaluating update of we PTSD. the our PTSD. the intended start exploratory NYX-XXX Phase for study evaluate with mechanism in effects to as on study XXX of symptoms of PTSD initial, broad of unique the a is approximately novel time experienced

To all by the progressing XX% and in target study date, have enrollment tracking has and our we approximately of metrics enrollment well. been achieved

manage far disruptions by some so been have been pandemic, there have COVID-XX them. site we and While at mitigate on brought to the the level able

feasible. are required to sites of continuity, and with our patient investigator develop delivery virtual accommodations participant follow-up as support where working to appropriate these home drug are and We study such

moving and study enrollment sites investigators of keep the this our Given needs welfare at some PTSD, dedication of with and patients time, study we patient of [ph] specific continue in forward. interest it we feel is the perseverance of the to appreciate in this and to this

into will patients responsible to new make and enroll so every remains long and study do as feasible. We effort continue this as this to

of dialogue study, the will and continuous of evaluation our to COVID-XX CROs well-being our this close with and in including remain sites patient primary vigilant [ph] We impacts safety focus and on

uncertainty on completion the guidance COVID-XX, ongoing around study timing of anticipate we providing from a readout the future and at Given updated of date. data this expected

which Now read in let's diabetic discuss out fibromyalgia. in X studies Phase first two development neuropathy, NYX-XXXX, XXXX indications, patients is these X in conditions. pain our we and peripheral Phase painful clinical chronic with In

validated the biomarker effects central evaluated of first processing. study Our of on pain neuro-imaging in fibromyalgia NYX-XXXX

XXXX in and changes were meaningful correlated We resulted and these effects significant that biomarker fibromyalgia in statistically significant saw other that improvement pain statistically these clinically with in biomarkers symptoms. and

our we pain, compelling inform our we and criteria patients helped study reduction NYX-XXXX thickness study saw other of run painful dose Along of The chronic which design pain inclusion that exclusion patient for in selection, segments. in current with in validating aimed and side, these parameters at studies first DPN. are

enhances important and and brain receptor-mediated in Its on have who experienced that gets addresses improvement It processing tremendously observed imaging be in information pain Together, through into initial objectively activity patients compelling translates have into activity symptom these NYX-XXXX. of provided NMDA central abnormalities pain can that pathways. chronically. studies the signals

studies, to in first in and intended one we what studies on and studies. the have leveraging effect the these actively the We've screening sites those studies. Both studies fibromyalgia in Based period. validate week learned of a and involving in initial initiated are was and we over late two designed studies, start-up and painful X to all completed follow-up patients these XX been Xb evaluate in XXXX one Phase Phase DPN observed efficacy NYX-XXXX work of in the safety

patients COVID-XX temporarily both suspended on of to the enrollment into the of enrollments these caused screening and March by However, studies. new pandemic, XXtj in of challenges we light

in and forth in conducting studies, already FDA guidelines accordance Importantly, the patients have studies. and that in with enrolled may the continue set further by CDC protocols clinical these

these and a And future the CROs with anticipate we readouts to [ph] when studies resume appropriate guidance our the expected site at updating to We of timing it will our enrollment. around enrollment date and situation active closely this following top line maintain is monitor from continue very determine of the studies. commencement in these dialogue to

let's discuss NYX-XXX cognitive our treatment disease. associated of Finally, the of for Parkinson's with development impairment

published Movement translatable of with validated The Disorders, saw in in deficits. non-human recently primates, cognitive model reversal results a Journal we highly striking As durable in NYX-XXX we and remarkable showing and

This on with potential to in those X the Parkinson's last Based enthusiastic first for were Phase cognitive cognitive will of NYX-XXX evaluate study exploratory impairment time. data, Parkinson's safety excited patients in and the our NYX-XXX we very and initiate December. of patients study benefits first mild

are COVID-XX medical patients, new vulnerable of suspend study to However, the have Despite on may in we those due suspension patients more on and consistent study the to of to the enrollment particular guidance. risks decided enrollment the continue, in hold by this patients these with based well. already who the new posed as protocol

NYX-XXX plans at are our investigation of and deficits patients this we on timelines t eager for to appropriate, cognitive When a reinitiate future and date. program we forward in look updates with our providing

and evaluation. the on we I that way the pandemic employees personnel our to the the of while and decisions studies safety has patients conducting of remained each forefront emphasize proceed consider of impact with health informed business, As at our study. of involved in The these COVID-XX factors on throughout best want our multiple how our to

of remote of Xth. protocols working and governor, stay Aptinyx' to order some we employees for effect ahead at and travel issued remains XXst at by Illinois instituted restrictions regards the least ago, our operations, which March weeks With home as in April

supply shipping to pandemic, of before have the escalation [ph] accelerate our for TAD investigational our steps facilitate we the uninterrupted to to taken studies. US of Fortunately, the products

to the an but We present we time. to any extended continue will comfortable effects at potential where track of about we supply regard with are disruption, feel

financing participation $XX also very position. health And The multiple have million stock we of we net and dedicated strong new, proceeds healthy as of the investors adding to care completed are quality of a balance. support the fortunate a to cash strong our already We number to existing were included pleased of sheet have a offering, well. investors. importantly In January, common balance cash approximately

course current we we that can financial into our ultimately multiple number regards studies. results, expect a to different provide expect data of enable Including But us of under will guidance to clinical that with We the XXXX. updated timing we provide cash of runway anticipate scenarios. following financing, our will clinical it of our and readouts hope the that runway with data resumption

call to I turn financial Ashish will over and end year to results. quarter now fourth the our review

Ashish Khanna

$XX.X we the at ended with you, with equivalents, quarter cash in of fourth $XXX.X Norbert. million compared Thank cash million XXXX. to the and balance end the sheet, Beginning

through offering should this from in including into As Norbert the $XX XXXX. enable million to fund through Aptinyx we operations common current our year in the next cash, XXXX January stock and expect year, net proceeds noted,

$X.X respectively, as fourth our for $X.X million XXXX were $X.X in and compared $X period million same quarter income With and for respect the to XXXX. to statement, million year and million revenues full the

related are to expect collaboration its Allergan which with come this conclusion our year. research contractual to revenues we to Our

not on fund Importantly, we reliant operations. are to revenues these our

of development same driven for XXXX and reduction NYX-XXX. spend to in decrease in heavily quarter by and XXXX. and respectively, primarily R&D research the remains year spend R&D and development. as to the in majority a million XXXX period during our clinical was and fourth $XX.X million full million compared expenses $XX.X The for million product The in $XX.X expenses concentrated $XX.X totaled related

to We to respectively, expenses ongoing including well XXXX. $X.X fees to XXXX same and This to related compared million non-cash professional from operations. spend business expense, full of reported as for period million in is increase XXXX million compensation, compensation G&A primarily and $X.X fourth $X.X $XX by support million and the employee for million the as driven year in costs in quarter XX.X XXXX as stock

the in XXXX of a the of $XX.X a period reported we fourth quarter $XX.X net net million to loss same compared for for million loss Finally, XXXX.

year full million, net loss $XX.X XXXX. $XX.X compared the XXXX, a for million loss to was For net

to over I'll now back call turn Norbert. the

Norbert Riedel

Ashish. Thanks,

personally Before we our that I mitigate COVID-XX. the deeply we convey want to I sincere doing business. begin by reiterate our taking those to to like effects and affected on are can everything Further, questions, to pandemic sympathy we would

impairment. Despite our product we our very cognitive enrollment the candidates pauses disorder about ongoing Phase the potential four have posttraumatic temporary of meaningfully in implemented studies, three patients to help stress optimistic pain, to to and chronic continue being with be X

But these This all us. to of for challenging new and to therapeutic is bring of ability ready questions. our confidence and Operator, resilience a the time in to are mission in have great patients. persist potential capabilities, now our we our certainly important commitment team I for options

Operator

first Thank you. Leerink. [Operator question Instructions] Goodman Marc comes of from Our SVB

open. is line Your

Marc Goodman

guys. Hey, Couple questions. Yes. of

still past need that enrollment PTSD when you the new in is study trying know us in sense give weeks so of to - trial? XX how be think you your finishing can out you the patients another First, sounds best normal Obviously, it a will figure just going couple up? just we're guess that of odd like the whatever, or was you

And company what a you what then second of potential all, the think about to Axsome fibromyalgia, it a Pfizer product product? reboxetine, and in for Thank you your I about as know was competitor product curious another you. licensed

Norbert Riedel

Okay. Mark, it address thanks and Catherine as kicked on with I'm for have by it have our going has question. as Andy, PTSD your Andy. weeks to going to past couple how well your in always, of the question been off as respect COO

Andy Kidd

Mark. Thanks, Yeah.

alluded trying eye to we keeping and not we're progress at obviously So level, very the of just Norbert site the accommodations the close where can. study make but enrollment, patient to visits on obviously a

good we've recently situation a know, week you seen sort day in day, reasonably can PTSD. But of I as progress appreciate. it's by week You think still by

long has going is really worth have the found weeks just and rest how But this that of at can't been it's what make progress the point. encouraging. to enrollment it's last hard that for there I in So predictions to say take two we about

Norbert Riedel

anything that. to add want you Catherine, to

Catherine King

No, I it well. covers that Thank think you.

Norbert Riedel

Okay.

up you Mark, have follow that. Sorry a did to

Marc Goodman

That's no. good. the And No, then other question.

Norbert Riedel

Ashish licensing other the in to have I'm an question in [indiscernible] go going you answer to Axsome give that. was Yes, on

Ashish Khanna

a like [ph] that reboxetine as much also duloxetine Thanks pretty serotonin-norepinephrine Hi, know a for question. therapy [ph] activity It's and in is fibromyalgia. which for Mark. you antidepressant the as reuptake Yeah. regard, patients inhibitor. Yeah, with

I need symptoms therapeutic significant those need - at the look think the all affecting a disorder, of space address progress as patients unmet complementary They that of to so various I across target root of welcome mechanism we than we a we're and space life major effects what know, the action that progress working very fibromyalgia It's domains. of additional and on. effects. and You options think for different have

forward progress its see to help eager and patients. we're so And

Marc Goodman

Excellent.

Operator

Thank you.

Our next of question is from Cantor Fitzgerald. Charles Duncan

open. Your line is

Charles Duncan

hear how Thanks and about Hi, ask guys. well, prepared Hopefully connected. to on for questions. a not the you I can on the I'm wanted what talked PTSD our Good. question program we're sure me you you taking remarks.

said you it's if it powering enrolled now, guess do what - XX% you assumptions next or that stop think to think and had the effect about so you steps? that I that demonstrate or I'm inform I and ability enrollment to the ability size about was that studies an wondering

Norbert Riedel

Terrific. Thanks, Charles.

have of first So the us mentioned a thereafter. signal here first to guides a is inpatient PTSD as out all and find study really the the our that we in study study past, is to goal next

for really statistical study. isn't study it its a powered So exploratory significance, finding signal

that difficult as numbers think we because goal close we when that be not and be then or continues and approximately it's study. to But to of do, communicated let I our That potentially this be can becomes possible goal. be point impossible there will think much stage our some XXX for to continues completion. reason necessary conclude done. to get that enrollment ideally to the our at to study all patients from said that, at at achieve the becomes study is had that in complete can to we us do as for enrollment Having this I as that If get as goal said when look what can what

Charles Duncan

would and replace about But deal do or that that or patients? helpful, thinking missing plans with guess, analysis That's data to assume statistical you Norbert. things I I you're different

Norbert Riedel

to Yeah, do do patients. has has missing go. of it dropout right. to with course, It maybe rates, depending increasing And how data with on things

dialogue close ultimately, to our our in differently. course we needs if data how necessary, and see with the statisticians with and team, treated of so will clinical be And that agency if

look so course that of data. from how meticulously part deviation and plan initial any at monitoring becomes is of are up We we and recording kept that the properly the

Charles Duncan

to believe you timing year of But and previous going end your that some from forward? the takeaways glean towards able consistent be the Okay. with data or that consider we'll

Norbert Riedel

continues currently goal. think we answered really the as we be about by I much definitive be that, can is that saying go are experience fluidity with as certainly that don't to COVID-XX, that to the have, Look, far I with our hope I it but

Charles Duncan

Yeah, similar has very that's fair. challenges. Everyone

the cash I us perhaps cash you guess that programs provide a two a believe guidance Ashish. a those were ask me Let to question do regard guided to balances, with could stop granularity follow little cash that be to what the up had would that XXX, XXXX if consider to into When you and more you to balances? changes I having year, XXXX for bit on say and

Ashish Khanna

Yeah.

chronic in is that the on So of pain on two it's are our surprise those then R&D spend ongoing studies, clinical no ongoing studies bulk and studies. largest pain and particular our studies

that reduced for period spend reasonable studies our those paused, will of to time. a of expect it's enrollment As is be

into get cash We'll to should guide that XXXX. us continue our

giving probably seek those guidance sense, more patients. how Really studies this or deciding think and these impact too that we out then the into once far I and to me far point they've to what studies – it's a the to updated when once for any As about provide have at timing we is and that tell. give impact of anticipated we during guidance, to enrolling restarted appropriate on as read will difficult on know XXXX

Charles Duncan

Got it.

you. helpful. good that's I and luck. appreciate Norbert, Ashish the Thank Okay, color

Norbert Riedel

you, Thank Charles.

Ashish Khanna

you. Thank

Operator

Thank you.

Laura next Chico Wedbush Securities. Our from of comes question

Your line is open.

Laura Chico

on already, thanks if for think but XXX talked was around what one guess And kind taking study? you your on, just you've clarify I and maybe of I dropouts this the of one afternoon. the to could good kind assumption discontinuation Hi, for questions. or

variability XXX here, two, about then patient here unfolding And on I the of you impact of demographic in just given kind the the guess thinking the the are the situation and study? how heterogeneity,

Norbert Riedel

much kick want you an question. Okay. to you Laura, off so with answer? for thank do Catherine, the

Catherine King

you. Thank Yes.

COVID-XX, So tracking up were well in in time issues dropout. leading - terms we of with toward to think pretty in of the leading I terms dropout the plan

that I with working that continued and the ways situation situations think we're where support unfolds individual we to trial participation in make carefully address the as watching very sites we can are individual in sense. to

be think the in factor heterogeneity we're might that time, to during files, it this to that so we different be I dataset that respect in our into in can becomes there and effort in ways our in variations doing method, important. variability, that what With making is measurements our every time document analysis event taken or variations but both also electronic the

it's think and that documentation those careful then the got making I again, analysis to the into going So factor details, the we've to attention forward. careful sure ability

Laura Chico

if purely for Thank place are I may. multiple in order up restart follow kind signal And before see to shelter the of things? availability, maybe what to Then need just a enrollment? what would related But of you when quick one orders, to guess restart Okay. then confluence you. looking this would site guess Is I in I you enrollment? you -

Norbert Riedel

Catherine, I think that you too. can tackle

Catherine King

Yeah. Sure.

things back our going to big is feeling so. of the to to I of right, to to the ability rest factors also everyday you just and the attend I of security a described home have think the to factor many leave and willingness a doing be normal to think visit, site of ability getting the of to staff life ability go patients work, the restart. in

ourselves to for We a do intend to use restart. this pause time well and position

of terms again account work, we'll monitoring close different get monitor world see the to may make times communication take the in as all that to we able and into and choices. But world, back we as broader those and in in situation differences clinical consider be trial conditions as locales the geographic to the So we both that develop.

Laura Chico

very Good guys. much, Thanks luck.

Norbert Riedel

Laura. you, Thank

Catherine King

you. Thank

Operator

you. Thank

Our next comes from question of Cowen. Ritu Baral

open. is Your line

Unidentified Analyst

Hi, My taking the dropouts the XXX that COVID? question Thanks Thank little is you. on trial. enrolled, you more wondering seen what granularity were guys. This to if increases [ph] prior the question. on meaning was was patients for I Have for suspending how progressing enrollment is any could in provide already Lyla. and a you to

Norbert Riedel

great. Okay,

we of running these I late my studies in So up the you screening. and are started mentioned as course are and know last prepared remarks that sites year and

the not it number the study has easy a I studies I early a is we PTSD little have impact think measure the sites clearly [ph] sense think - of give the It patients. therefore, just a has But resulting good overall like other as has impacted I on significantly of changed. is don't a it that we have to you on for and example on, study. on as had

Unidentified Analyst

then don't if And follow you. mind if Got you just I up.

briefly you're your that mentioned supply, supply… You the increasing

Norbert Riedel

Yes…

Unidentified Analyst

you currently currently do complete To if you meet – meet you were given the what for is the would have enough to that you suspended need eventually the needs, right trial? do supplies now, to trial XXX

Norbert Riedel

rather Andy don't have a of I'm but any I elaborate attention a lot sure supplies. remarks, disruptions making we have going question. to great have on Yeah, brief prepared because we in paid in my was little that really to more

Andy to to. And it add so I further over on hand to

Andy Kidd

the already Yeah, we for studies Yeah. manufactured so of and Thanks, sufficient investigational placebo all are have US. in product four actually Norbert. and supply our

you as We made the U.S. it's manufacturing we ahead situation was know, quite Norbert to as time think the over started this know just unfortunately in use all and building case. has. were sure shipped the I do U.S. in when situation organizations proactive manufacturing everything you supply outside Obviously we February it So of in unfolded then point just contract

they're time. done to most all the the we lead So to materials for but ready U.S. the yeah in short have have all we some need, a go, packaged we still be packaged, are and part that's fairly

So we're very comfortable.

the like think we being issues feel we have long reasonable envisage scenarios this which supply In comfortable things think would of we course we have I that. externally a very I with of we that the need. discussed life don't case that with are point at and shelf But delay,

Unidentified Analyst

you. helpful. very Okay, great. That's Thank

Andy Kidd

Thank you.

Operator

you. Thank

question Gary next Our Capital of BMO comes Nachman Markets. from

is line Your open.

Gary Nachman

hope Hi, pandemic. during guys. and you're Good afternoon safe this staying and healthy

do size studies enrollment, having in if targeted reduce potentially more back XXXX, DPN can that from the that? And even you even you Just fibro, compromised factor? to the risk change resume statistical overall diabetic does there's what if COVID-XX could patients delay? need to way, analysis the challenging of you long with And in it a previously just you any if when be of is additional not than terms

Norbert Riedel

Okay.

do kick questions. I Gary thanks going that in first So team all off I we're effort. it the a for think by to - Yeah, of

occasions the statistical on As studies. on we DPN we and meaningful powered the you have conducted studies we the information are Xb to X these several shared on we with significance previous Phase and built actually obtained Phase what have clinically achieve in current them fibromyalgia studies in endpoint a in is

ultimate I of point a of it study study study as next at cannot COVID-XX. the might fundamentals Who accomplish changed. the see not the do It the complicated here size have want the reduce in of because this so harder? not a have tackle will Is in that we of at to what the change we this more become And of the goal little point size foresee would the bit result we one? per wants the of I see but data, that to analysis this

Andy Kidd

which that's certainly fibromyalgia which concern that's in diabetes clearly how is diabetic on as there how and a population, is we'll risk additional known additional DPN compared to fiber not know, ability back evolve study, case ahead steps patients what think more think you course about is people vulnerable I the an risk an the are a needed take eye data we whether to I are populations and much and the of could the in mean, that for to believed DPN as I you of yet in comes as more so know. factor we'll know precautions a to yes, with gets it need still yeah, normal you guess that things study be restart with the I know don't life that just keep have be factor Yeah, to is learn general

Gary Nachman

guess you the XXX on in studies or re-enrollment I study know, versus if everyone's for viable? that I the that it of data And an of any you these period I'm months stop, Okay. just weeks like time and to with XXXX, allowable I starting mean that? studies? whether what's it's Is think going there sort frame for across it's through a industry. part year versus curious period allowed that know as is you is there a remain

Andy Kidd

the I think know - this of depend on lot general across the you a experience the will industry.

FDA know case. know the EMEA that there a you case clear times. these generally, and taken out are view have of unprecedented a are playbook come think I and by lot isn't guidance the the you things And of very guidance it's

accommodating were that as unusual don't way extent these a might some the are so not within seemed is there that within tolerating But we study and those. study going that situations allowing that to which they we occur and would think of may normally to think significant know. a the just not tolerated we I You kind be for encouraged guidance that suggest to yet know, a partisan I and of enrollment flexibility something be or in was read normally that

designed these studies studies. registration not are You as know

own the in a within right will with to lot probably that consultation be experts. our determine ultimately control So of

Gary Nachman

know Okay. across different maybe And DPN are then the any it's is assuming and going you fibro sites studies whether last I'm or question or PTSD be to there overlapping Parkinson's studies there sooner know, sites you the able board? might But across on sooner are restart others you that board there to or certain come so be certain than sites. are that

Norbert Riedel

Thank Catherine, could you take you. that.

Catherine King

may terms some do Yeah. be I those of of going the There who to care factor of is assessment an but enrolled. overlap well-being work driving and and for to is the think patients ability sites, the the welfare sites be of in

factor started had really today patients we've differences I terms think So good we'll in and decisions discussion DPN the patients that the get terms here a with about when in into we'll with of Parkinson's of to.

Gary Nachman

Thanks, guys. Okay.

Catherine King

Thank you.

Operator

comes Farr Our [Operator question next you. from Jessica JPMorgan. Thank Instructions] of

Your line is open.

Unidentified Analyst

is on taking XXXX certain the This what Jessica. are? on elaborate the we're In patients the PR, specific measures clinical to for questions. you Yuko mentioned continuity of our studies measures for support Hi. could the Thank you enrolled call taking you in

up you following on help asked Thank the suspension and think earlier the of you. about could XXX in the call, spend following the patient then question And studies? the us R&D new in XXXX temporary quarterly enrollment

Norbert Riedel

going XXXX was have answer you question. asked Catherine, you XXX? Yuko, I am to the to to or related it

Unidentified Analyst

Its XXXX.

Norbert Riedel

Okay. Catherine, take can you that please?

Catherine King

and address operating time, Yeah, also clinics. their institutions by and I individual in will this working investigators all with studies generally broadly to to it our we're and who me their concerns think for local carefully constraints and comply answer kind staff during let local procedures of the patients continue with required the sites, their and

a ensure and of large some timing that. delivery so like room could of be employ or types to be of And might we of the waiting a in contact something people study that could aren't drugs, with changing number there things that visits

visits that's is We that be to study to both design the and the and you. some and may Norbert, that of individual to clearly patients remote those being trying also sort where respond specifically. facing unique the challenges allow again for we of are sites the those appropriate we're measured. to back needs customizing and data that But sure

Ashish Khanna

financing look as spend know, sheet of We that I have the number the toward continues us think With to and with the is that projections This Yuko. serve different up well you is strong. at regard guiding of durability quite balance early scenarios our to a as been we again we cash in January Hi, talked =Ashish. under cash that serves think we which long modeled pandemic determined that pauses. studies we're be imagine the this our or those gets into path that whether well the that out across these that's the impacts can it XXXX to of scenarios we've how us regard through have as even out we you we to efforts and XXXX way enrollment across confident has cash understand with the all into really in well quite

we tied the the enrollment the In of is possibly spend temporarily of that largely expect and even enrollment. to spend would on that expect reduced moment, as period R&D that we duration we're of up the a for in meantime restarting pause course for at R&D so would as paused studies a reduction patient which

Unidentified Analyst

you. Thank

Operator

Thank closing no turn to at any over this I'm remarks. you. questions back call showing time. for I Norbert further the

Norbert Riedel

and call. further Thank to you, the your your particular please for as day. We under well updates We of circumstances your become and operator. attention your safe, to the And rest and on being enjoy to stay look be you communicating in all available. these and appreciate questions for time forward they thank

Operator

joining today. you Thank for us

disconnect.+ may now You